Monday, January 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Parkinson’s Drug May Help Recovery from Nerve Agent Exposure

by Global Biodefense Staff
September 22, 2014

Research findings recently published in the journal of Neurotoxicology and Teratology show a promising drug candidate to improve recovery from exposure to Soman, an extremely toxic nerve agent that inhibits the cholinesterase enzyme.

Caramiphen, an anticholinergic used in the treatment of Parkinson’s Disease, has antiglutamatergic properties via interactions at the N-methyl-D-aspartate (NMDA) receptor and anticonvulsant effects through the facilitation of gamma-Aminobutyric acid (GABA) inhibition in the basolateral amygdala part of the brain.

These characteristics of Caramiphen reduce seizure duration, body weight loss, motor and cognitive deficits, and brain damage frpm Soman exposure compared to standard therapy alone.

The research was sponsored by the Defense Threat Reduction Agency and conducted by the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD).

The researchers at USAMRICD, managed by DTRA’s Dr. Allen Duplantier, found that caramiphen edisylate administered to rats 30 minutes after seizure onset from Soman exposure worked effectively as an adjunct treatment to the standard therapy of atropine sulfate, oxime (HI-6), and diazepam.

These findings suggest that drug therapies with a combination of anticholinergic, NMDA antagonistic, and GABA enhancing effects might improve the long-term outcome following exposure to a seizure-inducing dose of Soman when added to the post nerve agent exposure regimen used on the battlefield.

Read more at the journal of Neurotoxicology and Teratology: Caramiphen edisylate as adjunct to standard therapy attenuates soman-induced seizures and cognitive deficits in rats.

Source: JSTO in the News, adapted.

Tags: Antitoxins

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC